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Intracellular trafﬁckingGene transfer applications with adenovirus (Ad) type 5 are limited by its native tropism, hampering their use
in several cell types. To address this limitation, several Ad vectors bearing chimeric ﬁber have been produced
to take advantage of the different cellular receptors used by other subgroups of Ads. In this study, we have
compared the transduction efﬁciency of Ad5 and the chimeric Ad5/F35 in primary human B lymphocytes
and B-cell lines as a function of the developmental stage. We found that transduction efﬁciencies of the two
Ads differ independently of their targeted cellular receptor but are related to the intracellular localization of
the virus. In efﬁciently transduced cells, Ads were localized in early endosomes or cytosol, whereas in poorly
transduced cells they were localized within late endosomes/lysosomes. Finally, we demonstrate that
treatment of cells with phosphatase inhibitors known to redirect endocytosis towards caveolae, increased
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Adenoviruses (Ads) have the ability to achieve efﬁcient targeting of
their genome to the nucleus of infected cells, making them useful tools
in gene transfer experiments (Greber and Kasamatsu, 1996; Leopold
and Crystal, 2007; Wilson, 1996). Ads can efﬁciently transduce both
proliferating and quiescent cells, and achieve transgene expression
withinhours (Neeringet al., 1996;Nevinset al., 1997).Moreover, Adsdo
not integrate their DNA into the host cell genome, thus leaving the
geneticmaterial of host cells intact. These properties allow reproducible
gene expression levels while simultaneously eliminating any undesir-
able effects related to the site of integration,making Ads attractive tools
for the study of transgene effects in transduced cells (Kay et al., 2001).
Over 100 different wild-type Ads have been isolated, and about half of
them are of human serotype. Among these, Ad subgroup C types 2 and 5
(Ad2andAd5) aremost commonlyusedasgene transfer vectors. TheAd
ﬁber knob mediates binding to the coxsackie/adenovirus receptor
(CAR) on host cells, allowing subsequent internalization by interacting
with αVβ3 integrins (Wickham et al., 1993). However, human
haematopoietic cells, including lymphocytes, express low levels of
CAR andαVβ3 integrins (Colin et al., 2004;Huang et al., 1997;McNees et
al., 2004), resulting in poor adenoviral transduction efﬁciencies(Neering et al., 1996; Rebel et al., 2000) for these cells. A new adenoviral
vector system (Ad5/F35) was recently developed by substitution of
Ad5-based vector ﬁbers with those of a human subgroup B Ad serotype
35 (Havenga et al., 2002; Knaan-Shanzer et al., 2001; Shayakhmetov et
al., 2000). This new vector utilizes the ubiquitous CD46 molecule as
receptor for entry into host cells (Gaggar et al., 2003). This chimeric
Ad5/F35 vector efﬁciently transduces human haematopoietic progen-
itor cells (Shayakhmetov et al., 2000), dendritic cells (Rea et al., 2001),
primary human T, NK and B lymphocytes (Cayer et al., 2007; Jung et al.,
2005; Schroers et al., 2004), primary chronicmyeloid leukemia cells and
chronic lymphocytic leukemia B cells (Nilsson et al., 2004) and B-type
acute lymphoblastic leukemia cells (Yotnda et al., 2004).
Several studies have examined the intracellular trafﬁcking of Ad
subgroup C (Leopold and Crystal, 2007); however, most of these were
derived fromcultured cell lines includingHeLa,HEK293andA549cells. To
our knowledge, only one study has addressed the intracellular fate of Ad5
in lymphoid cells (Colin et al., 2004), and none dealt speciﬁcally with
normal human B lymphocytes. For Ad subgroup B, including Ad5/F35,
only two studies investigated the intracellular trafﬁcking in HeLa and
A549 cells (Miyazawa et al., 2001; Shayakhmetov et al., 2003). These
reports revealed that cellular trafﬁcking of Ad subgroup C (Ad5) differs
from that of subgroup B (Ad7 and Ad/F35), in that Ad5 rapidly escapes
early endosomes, whereas Ad7 and Ad5/F35 accumulate in late
endosomes. Moreover, it has been demonstrated that in HeLa and A549
cells, the selection of intracellular trafﬁcking routes is determined by the
ﬁberknobandthecellular receptor (Miyazawaetal., 2001; Shayakhmetov
et al., 2003).
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intracellular fate of Ad5 in comparison to that of Ad5/F35 in lymphoid
cells, including normal human B lymphocytes. We demonstrated that
the selection of intracellular trafﬁcking routes is not only determined
by the ﬁber knob domain and the cellular receptor, but mainly by the
targeted cell type. Moreover, intracellular entry routes can be
modiﬁed by exposing cells to phosphatase inhibitors.
Results
Transduction efﬁciency of Ad5 and Ad5/F35 in various B-lymphocyte
lineage cells
We have used two previously constructed Ads, Ad5-EYFP and Ad5/
F35-EYFP, containing identical expression cassettes for the EYFP reporter
gene (Cayer et al., 2007; Jung et al., 2005) for this study. Ad5-EYFP has an
unmodiﬁed Ad5 capsid and relies upon CAR as cellular receptor, whereas
Ad5/F35 has a modiﬁed ﬁber bearing the knob domain of human
serotype 35, thereby modifying its tropism for CD46 as cellular receptor.
We have previously demonstrated that Ad5/F35 was substantially more
efﬁcient for gene transfer into B lymphocytes thanAd5 (Cayer et al., 2007;
Jung et al., 2005). However, we noticed variations in adenovirus-
mediated transgene expression among normal human B lymphocytes
from different donors and at various B-cell differentiation stages (Jung et
al., 2005). We sought to gain further insights into these variations using
two adenoviruses with different tropisms.
Eight B-lymphocyte cell lines corresponding to distinct stages of B-
lymphopoiesiswere investigated: SupB15 (pre-B); Raji, Ramos, Namalwa
andDaudi (mature B lymphocytes); L363, RPMI andU266 (plasma cells).
Normal human peripheral blood B lymphocytes from three distinct
donorswere also studied, aswell asHEK293 cells, as these cells are highly
permissive to both types of adenoviruses.Weﬁrst analyzed EYFP reporter
gene expression after infectionwith Ad5-EYFP or Ad5/F35-EYFP at aMOI
of 500. As expected 100% of HEK293 cells were EYFP-positive following
infectionwith either adenovirus (Fig. 1), conﬁrming thehighpermissivity
of this cell line forAd5(Colinet al., 2004)andAd5/F35(Cayer et al., 2007).
In contrast, normal human B lymphocytes were poorly transduced by
Ad5, whereas Ad5/F35 was able to transduce these cells to some extent
(Fig. 1). However, we observed noticeable variations between samples
from different donors for both adenoviruses. For instance, B lymphocytes
from one donor were moderately permissive, with 45% and 20% EYFP-Fig. 1. Comparison of adenoviral transduction efﬁciencies between the chimeric Ad5/F35-EY
and lymphoid cells. Cells were infected with adenovectors at a MOI of 500 for one hour, as de
by ﬂow cytometry. Results represent the mean of four independent experiments, with erropositive cells when transduced with Ad5/F35 and Ad5, respectively,
whereas B cells from the other two donors were not as permissive, with
about 20% and 2–8% EYFP-positive cells after transduction with Ad5/F35
and Ad5, respectively. Broader variations in transduction efﬁciency of
both adenoviruseswere observed in cell lines of B-cell origin, as shown in
Fig. 1. Cell lines of plasmacell originwere efﬁciently transducedwith both
adenoviruses, especially RPMI and U266 cells (near 100% EYFP-positive
cells); L363, the least efﬁciently transduced cell among plasma cell lines,
still gave 64% and88%EYFP-positive cells after transductionwithAd5 and
Ad5/F35, respectively. Among mature B-cell lines, Daudi was the least
efﬁciently transduced,with around 20% EYFP-positive cells after infection
with either adenovirus, whereas Raji was strongly transduced by Ad5
(63% EYFP-positive cells) but much less by Ad5/F35 (17% EYFP-positive
cells). Ramos and Namalwa cells were poorly transduced by Ad5 (∼20%
EYFP-positive cells) and moderately transduced by Ad5/F35 (∼30–40%
EYFP-positive cells). Pre-B-cell lines (SupB15)were hardly transduced by
Ad5 (2% EYFP-positive cells); in contrast, these cells were fairly well
transduced by Ad5/F35, with 58% EYFP-positive cells after infection.
These results conﬁrmed our previous observation that Ad5/F35 were
more efﬁcient to transduce lymphoid cells than Ad5. Collectively, these
results clearly demonstrate that there are donor- and differentiation
stage-dependent variations in adenovirus transduction efﬁciency among
cells from the B-lymphocyte lineage.
Analyses of the level of EYFP expression in transduced cells by QPCR
conﬁrmed the results described above (data not shown). Ad5-EYFP
infection led to a 100- to 100000-fold increase in EYFP transcript in U266
cells compared the other B-lymphoid cell lines. However, similar levels of
EYFP transcript were detected in HEK293 and U266 cells, suggesting that
Ad5 transduced these cell lines with comparable efﬁciencies. Differences
in EYFP transcript levels among the various B-cell models used were less
pronounced when using Ad5/F35-EYFP, with 50- to 1000-fold higher
transcript levels in U266 cells compared to the other B-cell models.
Variations in surface CAR expression among B-lymphoid cell types
It has been reported that Ad5 requires CAR for cellular binding
and αvβ3 integrin for internalization (Wickham et al., 1993). Notably,
B-lymphoid cells do not express this integrin (Colin et al., 2004;
Huang et al., 1997; Rebel et al., 2000), suggesting that this membrane
protein is not essential for Ad5 internalization in B lymphocytes. We
have also observed a very low percentage (≤2%) ofαvβ3-positive cellsFP vector and the parental Ad5-EYFP vector in normal human B lymphocytes, HEK293
scribed inMaterials andmethods. EYFP expression was analyzed 48 h post-transduction
rs bars corresponding to standard deviations.
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compared to HEK 293 cells (data not shown). Additionally, it has
been shown that Ad5/F35 requires only CD46 for binding and
internalization (Gaggar et al., 2003; Shayakhmetov et al., 2000).
Therefore, variations in adenovirus transduction efﬁciency could be
attributed to the differential expression of their respective cellular
receptors. We sought to gain further insights into these differences in
transduction efﬁciency by analyzing CAR and CD46 protein levels in
lymphoid cell lines by ﬂow cytometry. Our results shown in Fig. 2
indicate that except for HEK293, Daudi and Raji, less than 50% of the
cells from the tested lymphoid lines express CAR. Surprisingly, U266
cells show a very low percentage of positive cells (15%), yet these cells
appeared fully permissive to Ad5 transduction in previous experi-
ments. Conversely, Daudi cells are non-permissive to Ad5 transduc-
tion, despite a higher percentage of CARpositive cells (85%) than
HEK293 (78%). Furthermore, Raji cells were fairly permissive to Ad5
transduction, with 70% EYFP-positive cells upon infection, even
though they expressed lower levels of CAR than Daudi cells. Clearly,
alternative pathways for Ad5 infection of lymphoid cell lines exist,
and CAR may not be necessarily involved.
In contrast to CAR, CD46 was expressed by the vast majority of the
cells of lymphoid origin that we have analyzed, including normal B
lymphocytes (Fig. 2), yet the permissivity of these cells to Ad5/F35
was low, except for plasma cell lines. Thus, as for Ad5, it appears that
Ad5/F35 transduction efﬁciency does not correlate with CD46
expression. Collectively, these observations suggest that adenovirus
transduction efﬁciency is not solely dependent on the adenoviral ﬁber
protein and cellular receptors as previously stated (Shayakhmetov
et al., 2003), but is also related to the identity of the infected cell.
Binding and uptake of Ad5 and Ad5/F35 by lymphoid cells
To further investigate the differences in transduction efﬁciency of
Ad5 and Ad5/F35 in lymphoid cells, we have performed qualitative
analysis of their respective binding and uptake. Adenoviruses were
labeled with carboxynaphthoﬂuorescein, and binding and uptake
analyses were performed on normal B lymphocytes, HEK293 and cellFig. 2. Analyses of CAR and CD46 expression in normal human B lymphocytes, HEK293 and
expressed as percentage of positive cells for CAR (grey bars) and CD46 (white bars).lines that showed diverse transduction efﬁciencies (SupB15, Daudi and
U266). Cellswere incubated in the presence of labeled adenoviruses. An
aliquotof cellswasanalyzedbyﬂowcytometry todetermine adenovirus
binding after a 60-minute incubation at 4 °C; a second aliquot was
further incubated for 30 min at 37 °C to allow adenovirus uptake. Cells
were trypsinized to remove cell surface-bound adenovirus particles and
uptake was quantiﬁed by ﬂow cytometry analysis. As shown in Fig. 3,
with lymphoid cell lines, percent binding and uptake for both
adenoviruses were similar. However, with normal human B lympho-
cytes, we observe less ﬂuorescein-positive cells in uptake experiments
than in binding experiments for both types of viruses. This result
indicates that not all attached adenovirus particles enter cells. Notably,
for all cell types analyzed, Ad5/F35 virus had higher binding and uptake
than Ad5. Moreover, among lymphoid cell lines, Daudi cells displayed
the highest adenovirus binding and uptake, yet they were poorly
permissive to Ad5 and Ad5/F35 transduction. Conversely, U266 cells,
which are fully permissive to adenovirus transduction, showed lower
virus binding and uptake. These results suggest that binding and
internalization are not the sole determinants of transduction efﬁciency,
and points to intracellular processing of viral particles as an additional
parameter inﬂuencing transduction.
Intracellular localization of Ad5 and Ad5/F35 in lymphoid cells
It is well-documented that adenoviruses enter cells via endocytic
pathways (see (Sieczkarski and Whittaker, 2002) for review). When
entering cells by endocytosis, adenoviruses ﬁrst localize in early
endosomes before experiencing one of three possible fates: i) escape
early endosomes and move to the nucleus; ii) move to recycling
endosomes to be excreted; or iii) move to late endosomes and either
escape to the nucleus or remain within lysosomes where they
eventually get degraded. Early endosomes and cytoplasm have a pH
of 6.5/7, whereas pH values for late endosomes and lysosomes are in
the range of 5.5/4.5. We have exploited these differences to analyze
intracellular trafﬁcking of adenoviruses. Ad5 and Ad5/F35 were
labeledwith the pH-sensitive ﬂuorophore carboxynaphthoﬂuorescein
(CNF), which requires neutral to alkaline pH (6.5/8) for maximallymphoid cells. CAR and CD46 expression was analyzed by ﬂow cytometry. Results are
Fig. 3. Binding and uptake of CNF-labeled Ad5 and Ad5/F35 in lymphoid cells. For binding experiments, cells were incubated with CNF-labeled adenoviruses at a MOI of 100 for one
hour on ice, as described in Materials and methods. Quantiﬁcation of cell-attached viral particles by ﬂow cytometry was performed after ﬁxation with 1% paraformaldehyde. For the
determination of the internalized fraction of CNF-labeled viruses, cells were resuspended in 100 µl of adhesion buffer after binding experiments, and incubated at 37 °C for 30 min.
Cells were diluted threefold with cold 0.05% trypsin–0.5 mM EDTA and incubated at 37 °C for an additional 10 min. Cells were pelleted and resuspended in one ml ice-cold PBS and
ﬂuorescence was analyzed by ﬂow cytometry as described above. Results represent the mean percentage of ﬂuorescein-positive cells from three independent experiments, with
errors bars corresponding to standard deviations.
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cence emission requires acid pH (lower than 6) and is non-ﬂuorescent
outside the cell (Harvey et al., 2008; Miksa et al., 2009; Moore et al.,
2008). Virus labeling with these dyes does not alter infectivity (data
not shown). Next, labeled adenoviruses were allowed to bind to cells
for 40 min at 4 °C and uptake was initiated by transferring cells
incubated with viruses at 37 °C. Analyses were performed after
50 min of incubation at 37 °C, at which time the majority of Ad5
particles localized to the perinuclear space (Leopold et al., 1998;
Miyazawa et al., 2001). For Ad5, the results of Fig. 4a indicate that
ﬂuorescence could only be detected in HEK293, SupB15 and U266
cells infectedwith CNF-labeled Ad5. These results clearly demonstrate
that Ad5 particles do not migrate to late endosomes, but rather stay in
early endosomes or escape rapidly to the cytoplasm as previously
suggested by Shayakhmetov et al. (2003). In contrast, faint ﬂuores-
cence was detected in B lymphocytes infected with CNF-labeled Ad5,
whereas strong ﬂuorescence could be detected in cells infected with
pHrodo-labeled Ad5. The latter ﬁnding suggests that in normal B
lymphocytes, Ad5 localize mainly within late endosomes or lyso-
somes. In Daudi cells, ﬂuorescence could be detected in cells infected
with either labeled adenoviruses. Taken together, these results
suggest that the selection of intracellular trafﬁcking routes taken by
internalized adenoviral particles depends largely on the identity of the
infected cell.
Results obtained with labeled Ad5/F35, shown in Fig. 4b, differ
markedly from those obtained with labeled Ad5. For HEK293, SupB15
and U266 cells, ﬂuorescence could be detected following infection with
CNF- and pHrodo-labeled Ad5/F35. However, ﬂuorescence was much
brighter with CNF-labeled Ad5/F35, suggesting that most Ad5/F35
remained in and/or escaped early endosomes towards either the nucleus
or the extracellular space, rather than being redirected towards later
endosomes/lysosomes as previously described for Ad5/F35 in HeLa cells
(Shayakhmetov et al., 2003). In contrast, normal B lymphocytes infected
with CNF- or pHrodo-labeled Ad5/F35 showed comparable ﬂuorescence
emission, whereas in Daudi cells, ﬂuorescence could only be detected
after infection with pHrodo-labeled Ad5/F35. These results clearly
demonstrate that the intracellular trafﬁcking of Ad5/F35 is cell-speciﬁc.
Finally, we failed to detect intracellular ﬂuorescence from labeled
adenoviruses when internalization times exceeding 50 min wereapplied. However, the EYFP reporter gene product could be detected
as soon as two hours after beginning the internalization incubation,
suggesting that adenovirus transduction, when occurring, is very
rapid (data not shown). Moreover, when internalization times
ranging from 15 to 30 min were applied, only CNF-labeled Ads
could be detected by ﬂuorescence emission analyses in all cell types
tested (data not shown). This suggests that Ads localize within early
endosomes in the ﬁrst 30 min that follow internalization, before
eventually migrating to late endosomes.
An alternative entry route for Ad5/F35
Inefﬁcient Ad5/F35 transduction of B lymphocytes is a major
challenge for testing gene function in these cells. One way to
circumvent a possible limitation of transduction would be to bypass
the endosome/lysosome entry route. Several viruses such as SV40,
murine polyomavirus, picornavirus, echovirus 1, and respiratory
syncytial virus (Gilbert and Benjamin, 2000; Kartenbeck et al., 1989;
Marjomaki et al., 2002; Pelkmans et al., 2001; Pelkmans et al., 2002;
Richterova et al., 2001; Werling et al., 1999) use caveolae as a route of
cellular entry, bypassing the traditional endosome/lysosome pathway
(Pelkmans et al., 2001). Internalizations involving caveolae proceed
more slowly, and the resulting vesicles do not become acidiﬁed;
however this process is not constitutive, and only occurs upon cell
stimulation (Thomsen et al., 2002). Several studies have shown that
caveolae endocytosis can be increased by treating cells with
phosphatase inhibitors such as okadaic acid (Tagawa et al., 2005;
Thomsen et al., 2002). We therefore determined the transduction
efﬁciency of Ad5/F35-EYFP in SupB15 and Daudi cells upon okadaic
acid treatment. As shown in Fig. 5a, the percentage of EYFP-positive
SupB15 cells increased from 65% in untreated cells to 85% and 95% in
cells treated with 50 nM and 25 nM okadaic acid, respectively; no
increases in transduction efﬁciency were observed in SupB15 cells
treated with 100 nM okadaic acid. The same compound had similar
effects on Daudi cells: the percentage of EYFP-positive cells increased
from 5% in untreated cells to 25%, 24% and 45% in cells treated with
100 nM, 50 nM and 25 nM okadaic acid, respectively. We have also
analyzed the effects of okadaic acid on Ad5/F35-EYFP transduction
efﬁciency in normal human B lymphocytes. As shown in Fig. 5b,
Fig. 4. Intracellular trafﬁckingof adenoviruses in lymphoidcells. Intracellular localizationof CNF-orpHrodo-labeledadenoviruses (MOI=100) after a 40-minutebinding incubationat4 °C
and a 50-minute internalization incubation at 37 °C, analyzed by ﬂuorescence microscopy. a) Ad5. b) Ad5/F35. The representative ﬁelds are shown at a magniﬁcation of ×1000.
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acid, the percentage of EYFP-positive cells increased from 35% to 65%,
respectively. Transduction efﬁciency declined (45% to 55%) with
higher concentrations of okadaic acid. Finally, we have observed that
concentrations of okadaic acid ≥50 nM have cytotoxic effects on B
lymphocytes and B-cell lines (data not shown).
Taken together, our results clearly demonstrate that Ad5/F35
transduction efﬁciency can be signiﬁcantly increased in lymphoid
cells by the use of phosphatase inhibitors, such as okadaic acid.
Discussion
We have shown that transduction efﬁciency of Ad5 and Ad5/
F35, which utilize distinct cellular receptors, varies among human
B lymphocyte from different donors and lineages. Previous studies
have shown that transduction efﬁciency could be modulated by
intracellular trafﬁcking, which is inﬂuenced by the cellular receptor
used by the adenovirus and the structure of the adenoviral ﬁber andknob (Miyazawa et al., 1999, 2001; Shayakhmetov et al., 2003).
However, these studies were performed on only two cell lines, HeLa
and A549 cells. Recently, Colin et al. (2004) demonstrated than
lymphoid cells are differentially permissive to Ad5; unfortunately,
these authors did not provide any data for Ad5/F35. Our study, which
includes several cell lines from lymphoid origin as well as normal
human B lymphocytes, demonstrates that there is no direct correlation
between transduction efﬁciency and cellular receptor expression for
both types of viruses. For instance, only 15% of U266 cells express CAR,
yet these cells are highly permissive to Ad5 transduction, as are HEK293
cellswhere CAR is expressed in 80% of the cells. In contrast, 85% of Daudi
cells are positive for CAR, but this cell line is not permissive to Ad5
transduction. Furthermore, Raji cellswere fairly permissive to Ad5,with
70% of the cells EYFP-positive after infection, yet CAR expression in Raji
is lower than in Daudi cells. Moreover, while CD46, the cellular receptor
for Ad5/F35, is ubiquitously expressed, some cells remain poorly
permissive to this adenovirus. Collectively, these observations indicate
that the structure and/or level of expression of the cognate adenovirus
Fig. 5. Ad5/F35-EYFP transduction efﬁciencies in lymphoid cells and normal human B lymphocytes. Cells were treated for four hours with okadaic acid at the indicated
concentrations and infected with Ad5/F35-EYFP at a MOI of 500 for one hour, as described in Materials and methods. EYFP expression was analyzed 48 h post-transduction by ﬂow
cytometry. a) SupB 15 and Daudi cell lines. b) Normal human B lymphocytes. Results are expressed in percentage of EYFP-positive cells.
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McNees et al. (2004) have reported a study of adenovirus gene
expression in T-lymphoid cell lines that reached conclusions similar to
those presented herein. The authors showed that restoring expression
of CAR failed to make naturally restrictive T cells more permissive for
adenovirus in spite of the apparent delivery of virus into the cell. As for
our observations, one could speculate that Ads might be trapped in late
endosome/lysosomes in T-lymphoid cells as well.
An intriguing point thatwe noticed is the high transduction efﬁciency
of Ad5 in U266, L363 and RPMI cells, given that most of these cells lack
CAR expression. However, Colin et al. (2005, 2004) previously showed
that Ad5 efﬁciently transduces U266 cells using a lipid raft/caveolae
endocytic route; the same pathway might also be working in the twoother plasma cell lines. In any event, the possibility that Ad5 bypasses the
traditional endosome/lysosome entry route opens new avenues to
increase Ad5 transduction efﬁciency in presumably non-permissive cells.
One of the major points of the present study is that adenovirus
transduction efﬁciency depends largely on cell type-speciﬁc intracel-
lular trafﬁcking routes. We have used pH dependent ﬂuorophores to
analyze the subcellular localization of labeled adenovirus particles. It
has previously been shown that this labeling procedure does not alter
the natural trafﬁcking of adenovirus (Colin et al., 2004; Miyazawa
et al., 1999, 2001; Shayakhmetov et al., 2003), allowing pHrodo and
carboxynaphthoﬂuorescein to become powerful tools for the study of
endocytosis and phagocytosis (Harvey et al., 2008; Miksa et al., 2009;
Moore et al., 2008; Thomas et al., 1979). Using these ﬂuorophores, we
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trafﬁcking routes for Ad5 and Ad5/F35 viruses, and that these pathways
operate independently of the presence or absence of speciﬁc cellular
receptors. In cellswith low transduction efﬁciency,mostAd5orAd5/F35
particles are directed towards late endosomes/lysosomes. In contrast, in
cells that are highly permissive to adenovirus transduction, most Ad5 or
Ad5/F35 particles localize within early endosomes or cytosol. Notably,
Ad5/F35 couldbedetected in both types of endosomes innormal human
B lymphocytes, inwhich an intermediate level of transduction efﬁciency
is observed with this virus. Our results suggest that the intracellular
localization of internalized adenovirus is a key determinant of the
transduction efﬁciency. Following theirmigration to late endosomes and
lysosomes, adenoviruses are exposed to a low pH, protease-rich
environment that might eventually lead to their degradation. The lack
of adenoviral transgene expression might result from such a lysosomal
degradation. However, one cannot exclude the possibility that some
adenoviruses exploit the low pH environment to their advantage and
escape late endosomes, as previously described for Ad5/F35 and
adenoviruses from subgroup B (Miyazawa et al., 1999, 2001; Shayakh-
metov et al., 2003). This possibility could explain the faint transgene
expression observed in Daudi cells and normal human B lymphocytes.
Alternatively, low or absent transgene expression could also be
attributed to the endocytic recycling pathway that would extrude
adenovirus particles outside the cells.
Factors determining which intracellular trafﬁcking routes are
effective in a given cell remain to be investigated. We observed that
HEK293 andplasma cell lines (L363, RPMI andU266), all highly active in
proteins synthesis and speciﬁcally immunoglobulins for plasma cell
lines, are also highly permissive for Ad5 and Ad5/F35. In contrast, Ad5
and Ad5/F35 transduction efﬁciencywas low or intermediate in normal
human B lymphocytes, SupB15 (pre-B), Raji, Ramos, Namalwa and
Daudi (mature B lymphocytes); these cells are generally less active than
plasma cells and show comparatively lowprotein synthesis activity.We
hypothesize that the protein synthesis activity of a given cell might
dictate the intracellular trafﬁcking of adenovirus. In cells with low
protein synthesis activity, adenoviruses might be trapped in late
endosomes/lysosomes, whereas in cells actively synthesizing proteins,
adenoviruses might be able to escape early endosomes and gain access
to the cytosol and eventually the nucleus where transcription of viral
genes takes place. Alternatively, the lipid raft/caveolae endocytic route
might allow for an efﬁcient transduction as well.
Another important ﬁnding of our study is that Ad5/F35 transduction
efﬁciency can be signiﬁcantly increased in lymphoid cells following
phosphatase inhibitors treatment. Such treatment has previously been
shown to stimulate caveolae endocytosis (Tagawa et al., 2005; Thomsen
et al., 2002). This suggest that Ad5/F35 transduction efﬁciency could be
signiﬁcantly increased in lymphoid cells through stimulation of caveolae
endocytosis, circumventing the traditional endosome/lysosome entry
route to use instead caveolae to cross the plasma membrane. These
preliminary results will require further investigations to conﬁrm that
Ad5/F35 effectively enter cells by this pathway. However, it is reasonable
to assume that Ad5/F35 could also use this entry pathway following cell
stimulation, as has been reported for Ad5 inU266 cells (Colin et al., 2005).
Additionally, our results suggest that adenoviruses donot strictly rely on a
single canonical cellular receptor to enter the cell. This represents an
interesting avenue for the construction of new chimeric adenoviruses as
recently reported by Rogee et al. (2007), in that it might allow to take
advantage of non-classical endocytic pathways compensating for a low
transduction efﬁciency in certain cell types.
Materials and methods
Cell lines
SupB15 (pre-B acute lymphoblastic leukemia), Raji (Burkitt's lym-
phoma), Ramos (Burkitt's lymphoma), Namalwa (Burkitt's lymphoma),Daudi (Burkitt's lymphoma), L363 (plasma cell leukemia), RPMI
(multiple myeloma), U266 (multiple myeloma) and HEK293 (human
embryonic kidney) cell lines were obtained from ATCC (Manassas, MD,
USA). HEK293A (QBI-293A), purchased from Q.BIOgene (Carlsbad, CA,
USA), contain adenoviral genes E1 and E3 for in vitro adenovirus
production. SupB15, Namalwa, and Ramos cell lines were cultured in
Iscove's modiﬁed Dulbecco's medium (IMDM) (Invitrogen, Burlington,
ON, Canada) supplemented with 5% fetal bovine serum (FBS) (Invitro-
gen). Daudi, Raji, U266, RPMI and L363 cell lineswere cultured in Roswell
ParkMemorial Institutemedium(RPMI) (Invitrogen) supplementedwith
15% FBS (Invitrogen). HEK293 and HEK293Awere cultured in Dulbecco's
modiﬁed Eagle medium (DMEM) (Invitrogen) supplemented with 5%
FBS. Cell density and viability were monitored daily by Trypan blue dye
exclusion using a haemacytometer. All cell lines used weremycoplasma-
free.
Culture of human peripheral blood B lymphocytes
Blood samples were obtained from healthy individuals after
informed consent, and peripheral blood mononuclear cells were
prepared by density centrifugation over Ficoll-Paque (GE Healthcare
Biosciences Inc., Baie D'Urfé, QC, Canada). B lymphocytes were puriﬁed
by negative selection using the StemSep CD19mixture according to the
manufacturer's instructions (Stem Cell Technologies, Vancouver, BC,
Canada). Puriﬁed human B lymphocytes were N95% CD19+, as
determined by ﬂow cytometry. B lymphocytes were cultured at 37 °C
and 10% CO2 in a humidiﬁed atmosphere for ﬁve days in the presence of
SCM-7 membrane preparations expressing CD154 (ratio: 340×106
CD154 molecules/25000 B cells), as previously described (Cayer et al.,
2007), in IMDM supplemented with 10% Ultra-Low IgG FBS, 10 µg/ml
insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodiumselenite, antibiotics, (all
from Invitrogen), 100 U/ml IL-4 (R&D Systems, Minneapolis, MN, USA),
50 U/ml IL-2 and 25 U/ml IL-10 (both from PeproTech, Rocky Hill, NJ,
USA). These speciﬁc CD154 signal strength and cytokine cocktail are
required for activation and proliferation of human B lymphocytes
(Fecteau and Néron, 2003; Neron et al., 2005). Cell counts and viability
were evaluated in triplicate by Trypan blue dye exclusion. Cultured B
lymphocyteswere always N96% CD19+, and unless speciﬁed otherwise,
viability was N85%.
Production of adenoviral vectors
Ad5-EYFP and Ad5/F35-EYFP vectors were generated by in vivo
recombination in E. coli BJ5183 bacteria between pAdenoVator transfer
plasmids and pAdEasy-1 or pAdEasy-1/F35 adenoviral genomes using
the AdenoVator™ vector system (Qbiogene, Inc., Carlsbad, CA, USA).
Transfer plamids containing CMVi were purchased from Qbiogene. The
EYFP gene frompIRES-EYFP (Clontech, Palo Alto, CA, USA)was cloned in
the transfer plasmids described above. Recombinant adenovirus vectors
were transfected into QBI-293A cells (Qbiogene) using LipoFectamine
2000 (Invitrogen) and recombinant viruses were plaque-puriﬁed.
Viruses were ampliﬁed, puriﬁed and stored at −80 °C, as previously
described (Cayer et al., 2007). Viral stock titers the ranged between
3×108 and 1×109 infectious units/µl.
Adenoviral infection
Adenoviral infection of B lymphocytes was performed as previously
described (Jung et al., 2005). Brieﬂy, cells were washed with culture
medium and resuspended at a density of 1×107 cells/ml in 100 µl of
culture medium containing virus at a multiplicity of infection (MOI) of
500. After one hour at 37 °C, cells were transferred into 24-well culture
plates and diluted to a ﬁnal volume of one ml with their respective
culturemedium.Cellswere further incubated for 48 hafter transduction
before harvesting and analysis.
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Allophycocyanin-conjugated anti-CD19, FITC-conjugated anti-CD46,
PE-conjugated anti-CAR, and allophycocyanin-, PE-, and FITC-conjugated
isotype controls were used in staining procedures. All antibodies (Abs)
were murine IgG1 monoclonal Abs obtained from BD Biosciences
(Mountain View, CA, USA) or Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA) (anti-CAR). All stainings were performed using one µg of each
Ab for 1×106 cells at 4 °C. Cells were ﬁxed with 2% paraformaldehyde.
In all analyses, N95% of the cells were double negative when using
isotype-matched control Abs. Regions containing dead cells were gated
using 7-amino-actinomycin D staining, following the manufacturer's
instructions (BD Biosciences). The proportion of EYFP+ 7-AAD− cells was
determined by ﬂow cytometry (FACSCalibur, BectonDickinson, Palo Alto,
CA, USA). A minimum of 10000 gated cells were acquired, and analyses
were done with the CellQuest Pro software and FCSExpress software
(De Novo Software, Thornhill, ON, Canada).
Real-time quantitative PCR
Total RNA was isolated from 106 cells using the High Pure RNA
isolation kit (Roche Diagnostics, Laval, QC, Canada). One µg of RNA was
used to prepare cDNA using M-MLV reverse transcriptase (Invitrogen)
andoligo-dT.QuantitativePCR (QPCR) reactionswereperformedwith the
Perfecta SYBRgreen fastmix (Quanta Biosciences, Gaithersburg,MD, USA)
according to themanufacturer's instructions, on aMx3005P QPCR system
(Stratagene). For each time point, the average of three replicate reactions
was calculated. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as endogenous control for normalization. The following primer
sequenceswere used:GADPH F (5′ATG CAA CGGATT TGG TC 3′); GADPH
R (5′ TCT CGC TCC TGG AAG ATG GTG 3′); EYFP F (5′ACG TAA ACG GCC
ACA AGT TC 3′); EYFP R (5′ AAG TCG TGC TGC TTC ATG TG 3′). Primer
speciﬁcity was veriﬁed by melting curve analysis. The comparative Ct
method was used to calculate relative mRNA expression by normalizing
with a housekeeping gene control (GAPDH) and EYFP levels were
expressed relative to levels of the same transcript in infected U266 cells.
Labeling of adenoviruses with pH-sensitive ﬂuorophore
Two ﬂuorescent dyes were used. Carboxynaphthoﬂuorescein (CNF)
is characterized by a maximum ﬂuorescence emission at pH above 8,
and very low emission between pH 6 and 5, and ﬁnally no emission at
pH lower than 5. pHrodo™ ﬂuorescence emission can only be observed
at pH lower than 6, and is very strong at pH around 4.
Adenovirus capsids were labeled with CNF or pHrodo, according to
the manufacturer's protocol using a dye molecule/VP ratio of
2.68×106 and 2.37×106 respectively for CNF and pHrodo. Brieﬂy,
coupling with 5,6-carboxynaphthoﬂuorescein succinimidyl ester
(Invitrogen) and pHrodo™ succinimidyl ester (Invitrogen) was
performed in 0.1 M sodium carbonate, pH 8.3. 5,6-carboxynaphtho-
ﬂuorescein succinimidyl ester (400 µg/ml) or pHrodo™ succinimidyl
ester (400 µg/ml) were added to 12.5×109 VP and further incubated
for 30 min at room temperature. The reaction mixture was then
transferred to a dialysis chamber (Slide-A-Lyzer, 10000 MW cutoff,
Pierce, Rockford, IL, USA) and dialyzed against a solution of 10 mM
Tris–HCl (pH 7.5), 10 mM MgCl2, 150 mM NaCl and 10% glycerol at
4 °C to remove unincorporated chemicals.
Attachment and internalization assays
These assays are based on a published protocol (Shayakhmetov
et al., 2000). For attachment studies, 1×106 cellswere incubated for one
hour on ice with CNF-labeled adenoviruses at a MOI of 100 in 100 µl of
ice-cold adhesion buffer made up of culture medium supplemented
with 2 mM MgCl2, 1% bovine serum albumin, and 20mM HEPES. Cells
were pelleted by centrifugation for 5 min at 500 ×g and washed threetimes with one ml ice-cold PBS. Quantiﬁcation of labeled viral particles
was performed by ﬂow cytometry after cell ﬁxation with 1%
paraformaldehyde. To determine the fraction of CNF-labeled viruses
that were internalized, cells were infected as described above but after
the last wash, cells were resuspended in 100 µl of adhesion buffer and
incubated for 30 min at 37 °C. Cells were diluted threefold with cold
0.05% trypsin–0.5 mM EDTA solution and incubated at 37 °C for an
additional 10 min. This treatment removes 99% of cell-bound viruses
(Shayakhmetov et al., 2003). Finally, cells were pelleted and resus-
pended in one ml ice-cold PBS and ﬂuorescence was analyzed by ﬂow
cytometry as described above.
Analysis of adenoviruses trafﬁcking
75000 cells were incubated in 100 µl with labeled adenovirus
(MOI=500) for 40 min at 4 °C, followed by an additional 50-minute
incubation at 37 °C. Cells were then centrifuged at 60 ×g for 5 min onto
microscope slides using the cytospin technique. Cells were washed three
timeswithPBS,ﬁxedwith4% formaldehyde for 15 min, andwashed three
times in permeabilization buffer (PBS/0.1% Triton X-100). Cells were
blocked with PBS/0.1% Triton X-100/1% BSA for 10 min and incubated
with DAPI for 20 min. Finally, slides were washed three times with PBS/
0.1% Triton X-100 andmounted in ProlongGlod (Invitrogen). Slideswere
analyzed with a Nikon Eclipse TE200-S ﬂuorescence microscope.
Cell treatment with phosphatase inhibitors
Cells at a density of 5×105/ml were treated for 4 h with okadaic acid
(Sigma) at concentrations speciﬁed in the Results section. Cellswere then
washed three timeswith PBS-glucose and infectedwithAd5/F35-EYFP as
described above. 48 h postinfection, cells were analyzed by ﬂuorescence
microscopy and ﬂow cytometry.
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